;PMID: 11038163
;source_file_917.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..43] = [t:0..43]
;1)sentence:[e:49..127] = [t:49..127]
;2)section:[e:131..166] = [t:131..166]
;3)section:[e:170..301] = [t:170..301]
;4)sentence:[e:305..421] = [t:305..421]
;5)sentence:[e:422..595] = [t:422..595]
;6)sentence:[e:596..757] = [t:596..757]
;7)sentence:[e:758..1181] = [t:758..1181]
;8)sentence:[e:1182..1486] = [t:1182..1486]
;9)sentence:[e:1487..1659] = [t:1487..1659]
;10)sentence:[e:1660..1754] = [t:1660..1754]
;11)sentence:[e:1755..2017] = [t:1755..2017]
;12)sentence:[e:2018..2288] = [t:2018..2288]
;13)section:[e:2292..2310] = [t:2292..2310]
;14)section:[e:2316..2334] = [t:2316..2334]
;15)section:[e:2338..2383] = [t:2338..2383]

;section 0 Span:0..43
;Drug Metab Dispos. 2000 Nov;28(11):1343-51.
(SEC
  (FRAG (NNP:[0..4] Drug) (NNP:[5..10] Metab) (NNP:[11..17] Dispos)
        (.:[17..18] .) (CD:[19..23] 2000) (CC:[24..31] Nov;28-LRB-)
        (CD:[31..33] 11) (-RRB-:[33..34] -RRB-) (CD:[34..39] :1343)
        (::[39..40] -) (CD:[40..42] 51) (.:[42..43] .)))

;sentence 1 Span:49..127
;In vitro evaluation of the disposition of A novel cysteine protease
;inhibitor.
;[99..116]:substance:"cysteine protease"
;[117..126]:substance:"inhibitor"
(SENT
  (NP-HLN
    (NP
      (ADJP (FW:[49..51] In) (FW:[52..57] vitro))
      (NN:[58..68] evaluation))
    (PP (IN:[69..71] of)
      (NP
        (NP (DT:[72..75] the) (NN:[76..87] disposition))
        (PP (IN:[88..90] of)
          (NP (DT:[91..92] A) (JJ:[93..98] novel)
             (NN:[99..107] cysteine) (NN:[108..116] protease)
            (NN:[117..126] inhibitor)))))
    (.:[126..127] .)))

;section 2 Span:131..166
;Jacobsen W, Christians U, Benet LZ.
(SEC
  (FRAG (NNP:[131..139] Jacobsen) (NNP:[140..141] W) (,:[141..142] ,)
        (NNP:[143..153] Christians) (NNP:[154..155] U) (,:[155..156] ,)
        (NNP:[157..162] Benet) (NNP:[163..165] LZ) (.:[165..166] .)))

;section 3 Span:170..301
;Department of Biopharmaceutical Sciences, School of Pharmacy, University of 
;California, San Francisco, California 94143-0446, USA.
(SEC
  (FRAG (NNP:[170..180] Department) (IN:[181..183] of)
        (NNP:[184..201] Biopharmaceutical) (NNP:[202..210] Sciences)
        (,:[210..211] ,) (NNP:[212..218] School) (IN:[219..221] of)
        (NNP:[222..230] Pharmacy) (,:[230..231] ,) (NNP:[232..242] University)
        (IN:[243..245] of) (NNP:[247..257] California) (,:[257..258] ,)
        (NNP:[259..262] San) (NNP:[263..272] Francisco) (,:[272..273] ,)
        (NNP:[274..284] California) (CD:[285..290] 94143) (HYPH:[290..291] -)
        (CD:[291..295] 0446) (,:[295..296] ,) (NNP:[297..300] USA)
        (.:[300..301] .)))

;sentence 4 Span:305..421
;K11777 (N-methyl-piperazine-Phe-homoPhe-vinylsulfone-phenyl) is a potent, 
;irreversible cysteine protease inhibitor.
;[305..311]:substance:"K11777"
;[313..364]:substance:"N-methyl-piperazine-Phe-homoPhe-vinylsulfone-phenyl"
;[393..410]:substance:"cysteine protease"
;[411..420]:substance:"inhibitor"
(SENT
  (S
    (NP-SBJ
      (NP (NN:[305..311] K11777))
      (NP (-LRB-:[312..313] -LRB-)
          (NN:[313..364] N-methyl-piperazine-Phe-homoPhe-vinylsulfone-phenyl)
          (-RRB-:[364..365] -RRB-)))
    (VP (VBZ:[366..368] is)
      (NP-PRD (DT:[369..370] a) (JJ:[371..377] potent) (,:[377..378] ,)
              (JJ:[380..392] irreversible)
        (NML (NN:[393..401] cysteine) (NN:[402..410] protease))
        (NN:[411..420] inhibitor)))
    (.:[420..421] .)))

;sentence 5 Span:422..595
;Its therapeutic targets are cruzain, a  cysteine protease of the protozoan
;parasite Trypanosoma cruzi, and cathepsins B  and L, which are associated
;with cancer progression.
;[450..457]:substance:"cruzain"
;[462..479]:substance:"cysteine protease"
;[529..541]:substance:"cathepsins B"
;[529..539]...[547..548]:substance:"cathepsins"..."L"
(SENT
  (S
    (NP-SBJ (PRP$:[422..425] Its) (JJ:[426..437] therapeutic)
            (NNS:[438..445] targets))
    (VP (VBP:[446..449] are)
      (NP-PRD
        (NP
          (NP (NN:[450..457] cruzain))
          (,:[457..458] ,)
          (NP
            (NP (DT:[459..460] a)
               (NN:[462..470] cysteine) (NN:[471..479] protease))
            (PP (IN:[480..482] of)
              (NP
                (NP (DT:[483..486] the) (JJ:[487..496] protozoan)
                    (NN:[497..505] parasite))
                (NP (NNP:[506..517] Trypanosoma) (NNP:[518..523] cruzi))))))
        (,:[523..524] ,) (CC:[525..528] and)
        (NP
          (NP
            (NP
              (NML-1 (NNS:[529..539] cathepsins))
              (NN:[540..541] B))
            (CC:[543..546] and)
            (NP
              (NML-1 (-NONE-:[546..546] *P*))
              (NN:[547..548] L)))
          (,:[548..549] ,)
          (SBAR
            (WHNP-2 (WDT:[550..555] which))
            (S
              (NP-SBJ-2 (-NONE-:[555..555] *T*))
              (VP (VBP:[556..559] are)
                (VP (VBN:[560..570] associated)
                  (NP-2 (-NONE-:[570..570] *))
                  (PP-CLR (IN:[571..575] with)
                    (NP (NN:[576..582] cancer) (NN:[583..594] progression))))))))))
    (.:[594..595] .)))

;sentence 6 Span:596..757
;We evaluated the metabolism  of K11777 by human liver microsomes, isolated
;cytochrome P450 (CYP) enzymes, and  flavin-containing monooxygenase 3 (FMO3)
;in vitro.
;[628..634]:substance:"K11777"
;[671..700]:cyp450:"cytochrome P450 (CYP) enzymes"
;[707..740]:substance:"flavin-containing monooxygenase 3"
;[742..746]:substance:"FMO3"
(SENT
  (S
    (NP-SBJ (PRP:[596..598] We))
    (VP (VBD:[599..608] evaluated)
      (NP
        (NP (DT:[609..612] the) (NN:[613..623] metabolism))
        (PP (IN:[625..627] of)
          (NP (NN:[628..634] K11777)))
        (PP (IN:[635..637] by)
          (NP
            (NP (JJ:[638..643] human) (NN:[644..649] liver)
                (NNS:[650..660] microsomes))
            (,:[660..661] ,)
            (NP (VBN:[662..670] isolated)
              
              (NML
                (NML (NN:[671..681] cytochrome) (NN:[682..686] P450))
                (NML (-LRB-:[687..688] -LRB-) (NN:[688..691] CYP)
                     (-RRB-:[691..692] -RRB-)))
              (NNS:[693..700] enzymes))
            (,:[700..701] ,) (CC:[702..705] and)
            (NP
              (NP
                (ADJP (NN:[707..713] flavin) (HYPH:[713..714] -)
                      (VBG:[714..724] containing))
                (NN:[725..738] monooxygenase) (CD:[739..740] 3))
              (NP (-LRB-:[741..742] -LRB-) (NN:[742..746] FMO3)
                  (-RRB-:[746..747] -RRB-))))))
      (ADVP (FW:[748..750] in) (FW:[751..756] vitro)))
    (.:[756..757] .)))

;sentence 7 Span:758..1181
;K11777 was metabolized by  human liver microsomes to three major metabolites:
;N-oxide K11777 (apparent K(m)  = 14.0 +/- 4.5 microM and apparent V(max) =
;3460 +/- 3190 pmol. mg(-1). min(-1),  n = 4), beta-hydroxy-homoPhe K11777
;(K(m) = 16.8 +/- 3.5 microM and V(max) =  1260 +/- 1090 pmol. mg(-1).
;min(-1), n = 4), and N-desmethyl K11777 (K(m) = 18.3  +/- 7.0 microM and
;V(max) = 2070 +/- 1830 pmol. mg(-1). min(-1), n = 4).
;[758..764]:substance:"K11777"
;[823..834]:substance:"metabolites"
;[836..843]:substance:"N-oxide"
;[844..850]:substance:"K11777"
;[861..865]:quantitative-name:"K(m)"
;[869..881]:quantitative-value:"14.0 +/- 4.5"
;[882..888]:quantitative-units:"microM"
;[902..908]:quantitative-name:"V(max)"
;[911..924]:quantitative-value:"3460 +/- 3190"
;[925..946]:quantitative-units:"pmol. mg(-1). min(-1)"
;[957..977]:substance:"beta-hydroxy-homoPhe"
;[978..984]:substance:"K11777"
;[986..990]:quantitative-name:"K(m)"
;[993..1005]:quantitative-value:"16.8 +/- 3.5"
;[1006..1012]:quantitative-units:"microM"
;[1017..1023]:quantitative-name:"V(max)"
;[1027..1040]:quantitative-value:"1260 +/- 1090"
;[1041..1062]:quantitative-units:"pmol. mg(-1). min(-1)"
;[1076..1087]:substance:"N-desmethyl"
;[1088..1094]:substance:"K11777"
;[1096..1100]:quantitative-name:"K(m)"
;[1103..1116]:quantitative-value:"18.3  +/- 7.0"
;[1117..1123]:quantitative-units:"microM"
;[1128..1134]:quantitative-name:"V(max)"
;[1137..1150]:quantitative-value:"2070 +/- 1830"
;[1151..1172]:quantitative-units:"pmol. mg(-1). min(-1)"
(SENT
  (S
    (NP-SBJ-1 (NN:[758..764] K11777))
    (VP (VBD:[765..768] was)
      (VP (VBN:[769..780] metabolized)
        (NP-1 (-NONE-:[780..780] *))
        (PP (IN:[781..783] by)
          (NP-LGS (JJ:[785..790] human) (NN:[791..796] liver)
                  (NNS:[797..807] microsomes)))
        (PP-CLR (TO:[808..810] to)
          (NP
            (NP (CD:[811..816] three) (JJ:[817..822] major)
                (NNS:[823..834] metabolites))
            (::[834..835] :)
            (NP
              (NP (NN:[836..843] N-oxide) (NN:[844..850] K11777)
                (PRN (-LRB-:[851..852] -LRB-)
                  (FRAG
                    (S
                      (S
                        (NP-SBJ (JJ:[852..860] apparent)
                                (NN:[861..865] K-LRB-m-RRB-))
                        (VP (SYM:[867..868] =)
                          (NP
                            (QP (CD:[869..873] 14.0) (SYM:[874..877] +/-)
                                (CD:[878..881] 4.5))
                            (NN:[882..888] microM))))
                      (CC:[889..892] and)
                      (S
                        (NP-SBJ (JJ:[893..901] apparent)
                                (NN:[902..908] V-LRB-max-RRB-))
                        (VP (SYM:[909..910] =)
                          (NP
                            (NP
                              (QP (CD:[911..915] 3460) (SYM:[916..919] +/-)
                                  (CD:[920..924] 3190))
                              (NN:[925..929] pmol))
                            (PP (SYM:[929..930] .)
                              (NP (NN:[931..937] mg-LRB--1-RRB-)))
                            (PP (SYM:[937..938] .)
                              (NP (NN:[939..946] min-LRB--1-RRB-)))))))
                    (,:[946..947] ,)
                    (S
                      (NP-SBJ (NN:[949..950] n))
                      (VP (SYM:[951..952] =)
                        (NP (CD:[953..954] 4)))))
                  (-RRB-:[954..955] -RRB-)))
              (,:[955..956] ,)
              (NP (NN:[957..977] beta-hydroxy-homoPhe) (NN:[978..984] K11777)
                (PRN (-LRB-:[985..986] -LRB-)
                  (FRAG
                    (S
                      (S
                        (NP-SBJ (NN:[986..990] K-LRB-m-RRB-))
                        (VP (SYM:[991..992] =)
                          (NP
                            (QP (CD:[993..997] 16.8) (SYM:[998..1001] +/-)
                                (CD:[1002..1005] 3.5))
                            (NN:[1006..1012] microM))))
                      (CC:[1013..1016] and)
                      (S
                        (NP-SBJ (NN:[1017..1023] V-LRB-max-RRB-))
                        (VP (SYM:[1024..1025] =)
                          (NP
                            (NP
                              (QP (CD:[1027..1031] 1260) (SYM:[1032..1035] +/-)
                                  (CD:[1036..1040] 1090))
                              (NN:[1041..1045] pmol))
                            (PP (SYM:[1045..1046] .)
                              (NP (NN:[1047..1053] mg-LRB--1-RRB-)))
                            (PP (SYM:[1053..1054] .)
                              (NP (NN:[1055..1062] min-LRB--1-RRB-)))))))
                    (,:[1062..1063] ,)
                    (S
                      (NP-SBJ (NN:[1064..1065] n))
                      (VP (SYM:[1066..1067] =)
                        (NP (CD:[1068..1069] 4)))))
                  (-RRB-:[1069..1070] -RRB-)))
              (,:[1070..1071] ,) (CC:[1072..1075] and)
              (NP (NN:[1076..1087] N-desmethyl) (NN:[1088..1094] K11777)
                (PRN (-LRB-:[1095..1096] -LRB-)
                  (FRAG
                    (S
                      (S
                        (NP-SBJ (NN:[1096..1100] K-LRB-m-RRB-))
                        (VP (SYM:[1101..1102] =)
                          (NP
                            (QP (CD:[1103..1107] 18.3) (SYM:[1109..1112] +/-)
                                (CD:[1113..1116] 7.0))
                            (NN:[1117..1123] microM))))
                      (CC:[1124..1127] and)
                      (S
                        (NP-SBJ (NN:[1128..1134] V-LRB-max-RRB-))
                        (VP (SYM:[1135..1136] =)
                          (NP
                            (NP
                              (QP (CD:[1137..1141] 2070) (SYM:[1142..1145] +/-)
                                  (CD:[1146..1150] 1830))
                              (NN:[1151..1155] pmol))
                            (PP (SYM:[1155..1156] .)
                              (NP (NN:[1157..1163] mg-LRB--1-RRB-)))
                            (PP (SYM:[1163..1164] .)
                              (NP (NN:[1165..1172] min-LRB--1-RRB-)))))))
                    (,:[1172..1173] ,)
                    (S
                      (NP-SBJ (NN:[1174..1175] n))
                      (VP (SYM:[1176..1177] =)
                        (NP (CD:[1178..1179] 4)))))
                  (-RRB-:[1179..1180] -RRB-))))))))
    (.:[1180..1181] .)))

;sentence 8 Span:1182..1486
;All  three K11777 metabolites were formed by isolated CYP3A and their
;formation by  human liver microsomes was inhibited by the CYP3A inhibitor
;cyclosporine (50  microM, 54-62% inhibition) and antibodies against human
;CYP3A4/5 (100 microg of  antibodies/100 microg microsomal protein, 55-68%
;inhibition).
;[1193..1211]:substance:"K11777 metabolites"
;[1236..1241]:cyp450:"CYP3A"
;[1310..1315]:cyp450:"CYP3A"
;[1316..1325]:substance:"inhibitor"
;[1326..1338]:substance:"cyclosporine"
;[1340..1342]:quantitative-value:"50"
;[1344..1350]:quantitative-units:"microM"
;[1352..1358]:quantitative-value:"54-62%"
;[1375..1385]:substance:"antibodies"
;[1400..1406]:cyp450:"CYP3A4"
;[1400..1405]...[1407..1408]:cyp450:"CYP3A"..."5"
;[1410..1413]:quantitative-value:"100"
;[1414..1465]:quantitative-units:"microg of  antibodies/100 microg microsomal
;protein"
;[1467..1473]:quantitative-value:"55-68%"
(SENT
  (S
    (S
      (NP-SBJ-3 (DT:[1182..1185] All) (CD:[1187..1192] three)
         (NN:[1193..1199] K11777) (NNS:[1200..1211] metabolites))
      (VP (VBD:[1212..1216] were)
        (VP (VBN:[1217..1223] formed)
          (NP-3 (-NONE-:[1223..1223] *))
          (PP (IN:[1224..1226] by)
            (NP-LGS (VBN:[1227..1235] isolated) (NN:[1236..1241] CYP3A))))))
    (CC:[1242..1245] and)
    (S
      (NP-SBJ-4
        (NP (PRP$:[1246..1251] their) (NN:[1252..1261] formation))
        (PP (IN:[1262..1264] by)
          (NP (JJ:[1266..1271] human) (NN:[1272..1277] liver)
              (NNS:[1278..1288] microsomes))))
      (VP (VBD:[1289..1292] was)
        (VP (VBN:[1293..1302] inhibited)
          (NP-4 (-NONE-:[1302..1302] *))
          (PP (IN:[1303..1305] by)
            (NP-LGS
              (NP
                (NP (DT:[1306..1309] the) (NN:[1310..1315] CYP3A)
                    (NN:[1316..1325] inhibitor))
                (NP (NN:[1326..1338] cyclosporine))
                (PRN (-LRB-:[1339..1340] -LRB-)
                  (FRAG
                    (NP (CD:[1340..1342] 50) (NN:[1344..1350] microM))
                    (,:[1350..1351] ,)
                    (NP
                      (NML
                        (QP (CD:[1352..1354] 54) (HYPH:[1354..1355] -)
                            (CD:[1355..1357] 62))
                        (NN:[1357..1358] %))
                      (NN:[1359..1369] inhibition)))
                  (-RRB-:[1369..1370] -RRB-)))
              (CC:[1371..1374] and)
              (NP
                (NP (NNS:[1375..1385] antibodies))
                (PP (IN:[1386..1393] against)
                  (NP
                    (NP
                      (NML-2 (JJ:[1394..1399] human))
                      
                      (NML-1 (NN:[1400..1405] CYP3A))
                      (CD:[1405..1406] 4))
                    (SYM:[1406..1407] /)
                    (NP
                      (NML-2 (-NONE-:[1407..1407] *P*))
                      (NML-1 (-NONE-:[1407..1407] *P*))
                      (CD:[1407..1408] 5))))
                (PRN (-LRB-:[1409..1410] -LRB-)
                  (FRAG
                    (NP
                      (NP (CD:[1410..1413] 100) (NN:[1414..1420] microg))
                      (PP (IN:[1421..1423] of)
                        (NP (NNS:[1425..1435] antibodies)))
                      (PP (SYM:[1435..1436] /)
                        (NP
                          (NML (CD:[1436..1439] 100) (NN:[1440..1446] microg))
                          (JJ:[1447..1457] microsomal) (NN:[1458..1465] protein))))
                    (,:[1465..1466] ,)
                    (NP
                      (NML
                        (QP (CD:[1467..1469] 55) (HYPH:[1469..1470] -)
                            (CD:[1470..1472] 68))
                        (NN:[1472..1473] %))
                      (NN:[1474..1484] inhibition)))
                  (-RRB-:[1484..1485] -RRB-))))))))
    (.:[1485..1486] .)))

;sentence 9 Span:1487..1659
;CYP2D6 metabolized  K11777 to its N-desmethyl metabolite with an apparent
;K(m) (9.2 +/- 1.4 microM)  lower than for CYP3A4 (25.0 +/- 4.0 microM) and
;human liver microsomes.
;[1487..1493]:cyp450:"CYP2D6"
;[1507..1513]:substance:"K11777"
;[1521..1543]:substance:"N-desmethyl metabolite"
;[1561..1565]:quantitative-name:"K(m)"
;[1567..1578]:quantitative-value:"9.2 +/- 1.4"
;[1579..1585]:quantitative-units:"microM"
;[1603..1609]:cyp450:"CYP3A4"
;[1611..1623]:quantitative-value:"25.0 +/- 4.0"
;[1624..1630]:quantitative-units:"microM"
(SENT
  (S
    (NP-SBJ (NN:[1487..1493] CYP2D6))
    (VP (VBD:[1494..1505] metabolized)
      (NP (NN:[1507..1513] K11777))
      (PP-CLR (TO:[1514..1516] to)
        (NP (PRP$:[1517..1520] its)
           (NN:[1521..1532] N-desmethyl) (NN:[1533..1543] metabolite)))
      (PP (IN:[1544..1548] with)
        (NP
          (NP (DT:[1549..1551] an) (JJ:[1552..1560] apparent)
              (NN:[1561..1565] K-LRB-m-RRB-))
          (PRN (-LRB-:[1566..1567] -LRB-)
            (NP
              (QP (CD:[1567..1570] 9.2) (SYM:[1571..1574] +/-)
                  (CD:[1575..1578] 1.4))
              (NN:[1579..1585] microM))
            (-RRB-:[1585..1586] -RRB-))
          (ADJP
            (ADJP (JJR:[1588..1593] lower))
            (PP (IN:[1594..1598] than)
              (PP (IN:[1599..1602] for)
                (NP
                  (NP (NN:[1603..1609] CYP3A4)
                    (PRN (-LRB-:[1610..1611] -LRB-)
                      (NP
                        (QP (CD:[1611..1615] 25.0) (SYM:[1616..1619] +/-)
                            (CD:[1620..1623] 4.0))
                        (NN:[1624..1630] microM))
                      (-RRB-:[1630..1631] -RRB-)))
                  (CC:[1632..1635] and)
                  (NP (JJ:[1636..1641] human) (NN:[1642..1647] liver)
                      (NNS:[1648..1658] microsomes)))))))))
    (.:[1658..1659] .)))

;sentence 10 Span:1660..1754
;The  apparent K(m) for N-oxide K11777 formation by cDNA-expressed FMO3 was
;109 +/- 11  microM.
;[1674..1678]:quantitative-name:"K(m)"
;[1683..1690]:substance:"N-oxide"
;[1691..1697]:substance:"K11777"
;[1711..1715]:substance:"cDNA"
;[1726..1730]:substance:"FMO3"
;[1735..1745]:quantitative-value:"109 +/- 11"
;[1747..1753]:quantitative-units:"microM"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[1660..1663] The) (JJ:[1665..1673] apparent)
          (NN:[1674..1678] K-LRB-m-RRB-))
      (PP (IN:[1679..1682] for)
        (NP
          (NP (NN:[1683..1690] N-oxide) (NN:[1691..1697] K11777)
              (NN:[1698..1707] formation))
          (PP (IN:[1708..1710] by)
            (NP
              (ADJP (NN:[1711..1715] cDNA) (HYPH:[1715..1716] -)
                    (VBN:[1716..1725] expressed))
              (NN:[1726..1730] FMO3))))))
    (VP (VBD:[1731..1734] was)
      (NP-PRD
        (QP (CD:[1735..1738] 109) (SYM:[1739..1742] +/-) (CD:[1743..1745] 11))
        (NN:[1747..1753] microM)))
    (.:[1753..1754] .)))

;sentence 11 Span:1755..2017
;Based on the intrinsic formation clearances and the results of  inhibition
;experiments (CYP2D6, 50 microM bufuralol; FMO3 mediated, 100 mM  methionine)
;using human liver microsomes, it was estimated that CYP3A  contributes to
;>80% of K11777 metabolite formation.
;[1843..1849]:cyp450:"CYP2D6"
;[1851..1853]:quantitative-value:"50"
;[1854..1860]:quantitative-units:"microM"
;[1861..1870]:substance:"bufuralol"
;[1872..1876]:substance:"FMO3"
;[1887..1890]:quantitative-value:"100"
;[1891..1893]:quantitative-units:"mM"
;[1895..1905]:substance:"methionine"
;[1959..1964]:cyp450:"CYP3A"
;[1981..1985]:quantitative-value:">80%"
;[1989..2006]:substance:"K11777 metabolite"
(SENT
  (S
    (PP (VBN:[1755..1760] Based)
      (PP (IN:[1761..1763] on)
        (NP
          (NP (DT:[1764..1767] the) (JJ:[1768..1777] intrinsic)
              (NN:[1778..1787] formation) (NNS:[1788..1798] clearances))
          (CC:[1799..1802] and)
          (NP
            (NP (DT:[1803..1806] the) (NNS:[1807..1814] results))
            (PP (IN:[1815..1817] of)
              (NP
                (NP (NN:[1819..1829] inhibition) (NNS:[1830..1841] experiments))
                (PRN (-LRB-:[1842..1843] -LRB-)
                  (FRAG
                    (FRAG
                      (NP (NN:[1843..1849] CYP2D6))
                      (,:[1849..1850] ,)
                      (NP
                        (NML (CD:[1851..1853] 50) (NN:[1854..1860] microM))
                        (NN:[1861..1870] bufuralol)))
                    (::[1870..1871] ;)
                    (FRAG
                      (ADJP (NN:[1872..1876] FMO3) (VBN:[1877..1885] mediated))
                      (,:[1885..1886] ,)
                      (NP
                        (NP (CD:[1887..1890] 100) (NN:[1891..1893] mM))
                        (NP (NN:[1895..1905] methionine)))))
                  (-RRB-:[1905..1906] -RRB-))
                (VP (VBG:[1907..1912] using)
                  (NP (JJ:[1913..1918] human) (NN:[1919..1924] liver)
                      (NNS:[1925..1935] microsomes)))))))))
    (,:[1935..1936] ,)
    (NP-SBJ-1
      (NP (PRP:[1937..1939] it))
      (SBAR-2 (-NONE-:[1939..1939] *EXP*)))
    (VP (VBD:[1940..1943] was)
      (VP (VBN:[1944..1953] estimated)
        (NP-1 (-NONE-:[1953..1953] *))
        (SBAR-2 (IN:[1954..1958] that)
          (S
            (NP-SBJ (NN:[1959..1964] CYP3A))
            (VP (VBZ:[1966..1977] contributes)
              (PP-CLR (TO:[1978..1980] to)
                (NP
                  (NP
                    (QP (SYM:[1981..1982] >) (CD:[1982..1984] 80))
                    (NN:[1984..1985] %))
                  (PP (IN:[1986..1988] of)
                    (NP
                       (NN:[1989..1995] K11777) (NN:[1996..2006] metabolite)
                      (NN:[2007..2016] formation))))))))))
    (.:[2016..2017] .)))

;sentence 12 Span:2018..2288
;K11777 was a potent (IC(50)  = 0.06 microM) and efficacious (maximum
;inhibition 85%) NADPH-dependent  inhibitor of human CYP3A4 mediated
;6'beta-hydroxy lovastatin formation,  suggesting that K11777 is not only a
;substrate but also a mechanism-based  inhibitor of CYP3A4.
;[2018..2024]:substance:"K11777"
;[2039..2045]:quantitative-name:"IC(50)"
;[2049..2053]:quantitative-value:"0.06"
;[2054..2060]:quantitative-units:"microM"
;[2098..2101]:quantitative-value:"85%"
;[2103..2108]:substance:"NADPH"
;[2139..2145]:cyp450:"CYP3A4"
;[2155..2169]:substance:"6'beta-hydroxy"
;[2170..2180]:substance:"lovastatin"
;[2209..2215]:substance:"K11777"
;[2230..2239]:substance:"substrate"
;[2268..2277]:substance:"inhibitor"
;[2281..2287]:cyp450:"CYP3A4"
(SENT
  (S
    (NP-SBJ (NN:[2018..2024] K11777))
    (VP (VBD:[2025..2028] was)
      (NP-PRD
        (NP (DT:[2029..2030] a)
          (ADJP
            (ADJP (JJ:[2031..2037] potent)
              (PRN (-LRB-:[2038..2039] -LRB-)
                (S
                  (NP-SBJ (NN:[2039..2045] IC-LRB-50-RRB-))
                  (VP (SYM:[2047..2048] =)
                    (NP (CD:[2049..2053] 0.06) (NN:[2054..2060] microM))))
                (-RRB-:[2060..2061] -RRB-)))
            (CC:[2062..2065] and)
            (ADJP (JJ:[2066..2077] efficacious)
              (PRN (-LRB-:[2078..2079] -LRB-)
                (S
                  (NP-SBJ (NN:[2079..2086] maximum) (NN:[2087..2097] inhibition))
                  (NP-PRD (CD:[2098..2100] 85) (NN:[2100..2101] %)))
                (-RRB-:[2101..2102] -RRB-))))
          (ADJP (NN:[2103..2108] NADPH) (HYPH:[2108..2109] -)
                (JJ:[2109..2118] dependent))
          (NN:[2120..2129] inhibitor))
        (PP (IN:[2130..2132] of)
          (NP (JJ:[2133..2138] human)
            (ADJP (NN:[2139..2145] CYP3A4) (VBN:[2146..2154] mediated))
            (NML (NN:[2155..2169] 6'beta-hydroxy) (NN:[2170..2180] lovastatin))
            (NN:[2181..2190] formation))))
      (,:[2190..2191] ,)
      (S-ADV
        (NP-SBJ (-NONE-:[2191..2191] *))
        (VP (VBG:[2193..2203] suggesting)
          (SBAR (IN:[2204..2208] that)
            (S
              (NP-SBJ (NN:[2209..2215] K11777))
              (VP (VBZ:[2216..2218] is)
                (NP-PRD
                  (NP
                    (CONJP (RB:[2219..2222] not) (RB:[2223..2227] only))
                    (NP (DT:[2228..2229] a) (NN:[2230..2239] substrate))
                    (CONJP (CC:[2240..2243] but) (RB:[2244..2248] also))
                    (NP (DT:[2249..2250] a) (NN:[2251..2260] mechanism)
                        (HYPH:[2260..2261] -) (VBN:[2261..2266] based)
                        (NN:[2268..2277] inhibitor)))
                  (PP (IN:[2278..2280] of)
                    (NP (NN:[2281..2287] CYP3A4))))))))))
    (.:[2287..2288] .)))

;section 13 Span:2292..2310
;Publication Types:
(SEC
  (FRAG (NNP:[2292..2303] Publication) (NNP:[2304..2309] Types)
        (::[2309..2310] :)))

;section 14 Span:2316..2334
;Evaluation Studies
(SEC
  (FRAG (NN:[2316..2326] Evaluation) (NNS:[2327..2334] Studies)))

;section 15 Span:2338..2383
;PMID: 11038163 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[2338..2342] PMID) (::[2342..2343] :) (CD:[2344..2352] 11038163)
        (NN:[2353..2354] -LSB-) (NNP:[2354..2360] PubMed) (::[2361..2362] -)
        (NN:[2363..2370] indexed) (IN:[2371..2374] for)
        (NNP:[2375..2383] MEDLINE-RSB-)))
